Bispecific Antibodies in DLBCL: Patient Response
Experts explore early outcomes and patient candidacy factors for bispecific antibody therapy in diffuse large B-cell lymphoma (DLBCL) and discuss responses, real-world evidence, trends in patient outcomes, and selection biases.
EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential
EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL
EP: 3.Bispecific Antibodies in DLBCL Trials
EP: 4.Bispecific Antibodies in DLBCL: Patient Response
EP: 5.Future Insights on Bispecific Therapies
EP: 6.Overcoming DLBCL Treatment Hurdles
EP: 7.Patient Education and Monitoring in DLBCL Treatment
EP: 8.Implementing Bispecific Treatments
EP: 9.Bispecific Toxicity Management in DLBCL Care
EP: 10.Multidisciplinary Bispecific Care
EP: 11.Pharmacists: Bispecifics and Operational Role
EP: 12.Strategies for Reducing Bispecific Therapy Toxicities
EP: 13.Unmet Needs in Bispecific Therapy Access
EP: 14.Implementing Bispecific Antibodies in Lymphoma Care
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari, Mancini, and Ali discuss trends and outcomes of patients treated with bispecific therapies. Ali acknowledges that data is still maturing, with these drugs approved in May 2023. Anecdotally, patients, even in advanced therapy lines, show strong responses, while some refractory to chimeric antigen receptor (CAR) T-cell therapy exhibit lower responses.
The conversation anticipates significant research in this space, suggesting the prominence of this topic in conferences such as the 2024 American Society of Hematology Annual Meeting & Exposition. Mancini emphasizes 2 primary patient-driven factors for assessing bispecific candidacy: clinical appropriateness and patient fitness. He notes potential selection bias, as the off-the-shelf availability of bispecifics influences patient choices between them and CAR T-cell therapy. Operational considerations, including caregiver support, become crucial due to unique adverse effects like cytokine release syndrome and neurotoxicity.
As they await more real-world evidence, their discussion highlights the need for research and patient-centric considerations in the evolving landscape of DLBCL treatments.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
